Cash, cash equivalents and investments were $230.2M as of December 31, 2022, which is projected to fund operations into the first quarter of 2025. "We are encouraged with the initial proof of concept demonstrated in patients treated in our VBP101 study," said Robert Ang, Vor Bio’s president and CEO. "We remain focused on rapid enrollment and plan to share additional clinical data later this year. Our IND for VCAR33ALLO is on-track for submission in the first half of 2023 which, together with trem-cel, has the potential to transform outcomes for patients with blood cancers."
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on VOR:
- Vor Bio Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Company Update
- Vor Bio to Participate in Upcoming Investor Conferences
- First AML Patient Transplanted with Vor Bio’s Trem-cel Demonstrated Durable Engraftment through Multiple Mylotarg™ Cycles at Initial Dose Level
- Vor Bio presents clinical data from VBP101 Phase 1/2a study of trem-cel